Literature DB >> 30923177

The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!

Marius M Hoeper1, Marc Humbert2,3,4.   

Abstract

Entities:  

Year:  2019        PMID： 30923177     DOI： 10.1183/13993003.00038-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats.

Authors:  Jingjing Xu; Xiangnan Li; Siqi Zhou; Rui Wang; Mengxi Wu; Cheng Tan; Jingyu Chen; Zhiping Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.

Authors:  Yasmina Bauer; Simon de Bernard; Peter Hickey; Karri Ballard; Jeremy Cruz; Peter Cornelisse; Harbajan Chadha-Boreham; Oliver Distler; Daniel Rosenberg; Martin Doelberg; Sebastien Roux; Oliver Nayler; Allan Lawrie
Journal:  Eur Respir J       Date:  2021-06-24       Impact factor: 16.671

3.  Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD.

Authors:  Maha Fathy Mohamed; Asmaa Ali; Ahmad Abbas; Mohammad Shafiq Awad; Mohammad Gouda; Amany M Sediq
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-23

4.  The revised definition of pulmonary hypertension: exploring the impact on patient management.

Authors:  Gérald Simonneau; Marius M Hoeper
Journal:  Eur Heart J Suppl       Date:  2019-12-17       Impact factor: 1.803

5.  Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions.

Authors:  Richa Tyagi; Surya Kant; Akshyaya Pradhan; Anupam Wakhlu; Darshan Kumar Bajaj; Jyoti Bajpai
Journal:  Can Respir J       Date:  2021-11-28       Impact factor: 2.409

6.  A computational model of contributors to pulmonary hypertensive disease: impacts of whole lung and focal disease distributions.

Authors:  Behdad Shaarbaf Ebrahimi; Merryn H Tawhai; Haribalan Kumar; Kelly S Burrowes; Eric A Hoffman; Margaret L Wilsher; David Milne; Alys R Clark
Journal:  Pulm Circ       Date:  2021-11-18       Impact factor: 2.886

Review 7.  Role of environmental toxicants in the development of hypertensive and cardiovascular diseases.

Authors:  Ehsan Habeeb; Saad Aldosari; Shakil A Saghir; Mariam Cheema; Tahani Momenah; Kazim Husain; Yadollah Omidi; Syed A A Rizvi; Muhammad Akram; Rais A Ansari
Journal:  Toxicol Rep       Date:  2022-03-22

8.  Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension.

Authors:  Patryk Remiszewski; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Eberhard Schlicker; Justyna Klimek; Janusz Dzięcioł; Barbara Malinowska
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

9.  Impact of borderline pulmonary hypertension due to left heart failure on mortality in a multicenter registry study: A 3-year survivorship analysis.

Authors:  Yangyi Lin; Lingpin Pang; Shian Huang; Jieyan Shen; Weifeng Wu; Fangming Tang; Weiqing Su; Xiulong Zhu; Jingzhi Sun; Ruilin Quan; Tao Yang; Huijun Han; Jianguo He
Journal:  Front Cardiovasc Med       Date:  2022-08-12

10.  Plasticity and Enzymatic Degradation Coupled With Volumetric Growth in Pulmonary Hypertension Progression.

Authors:  Eun-Ho Lee; Seungik Baek
Journal:  J Biomech Eng       Date:  2021-11-01       Impact factor: 2.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.